Context Therapeutics Inc. (CNTX) Q1 2026 Earnings
CNTX·Reported May 6, 2026·Before market open
Diluted EPS came in at $-0.09 (-80.0% YoY), beat the $-0.12 consensus by $0.03.
Diluted EPS
$-0.09beat by $0.03
Consensus: $-0.12
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Context Therapeutics Inc.'s Q1 2026 earnings report.
Context Therapeutics Inc. (CNTX) reported Q1 2026 earnings on May 6, 2026 before market open.
Context Therapeutics Inc. reported diluted EPS of $-0.09 for Q1 2026.
EPS beat the consensus estimate of $-0.12 by $0.03.
Compared to the same quarter a year prior, diluted EPS declined 80.0% from $-0.05.
You can read the 10-Q periodic report (0001628280-26-031267) directly on SEC EDGAR. The filing index links above go to sec.gov.